Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation
- PMID: 9305589
- DOI: 10.1021/tx9700836
Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation
Abstract
The cytochrome P450-dependent covalent binding of radiolabel derived from phenytoin (DPH) and its phenol and catechol metabolites, 5-(4'-hydroxyphenyl)-5-phenylhydantoin (HPPH) and 5-(3',4'-dihydroxyphenyl)-5-phenylhydantoin (CAT), was examined in liver microsomes. Radiolabeled HPPH and CAT and unlabeled CAT were obtained from microsomal incubations and isolated by preparative HPLC. NADPH-dependent covalent binding was demonstrated in incubations of human liver microsomes with HPPH. When CAT was used as substrate, covalent adduct formation was independent of NADPH, was enhanced in the presence of systems generating reactive oxygen species, and was diminished under anaerobic conditions or in the presence of cytoprotective reducing agents. Fluorographic analysis showed that radiolabel derived from DPH and HPPH was selectively associated with proteins migrating with approximate relative molecular weights of 57-59 kDa and at the dye front (molecular weights < 23 kDa) on denaturing gels. Lower levels of radiolabel were distributed throughout the molecular weight range. In contrast, little selectivity was seen in covalent adducts formed from CAT. HPPH was shown to be a mechanism-based inactivator of P450, supporting the contention that a cytochrome P450 is one target of covalent binding. These results suggest that covalent binding of radiolabel derived from DPH in rat and human liver microsomes occurs via initial P450-dependent catechol formation followed by spontaneous oxidation to quinone and semiquinone derivatives that ultimately react with microsomal protein. Targets for covalent binding may include P450s, though the catechol appears to be sufficiently stable to migrate out of the P450 active site to form adducts with other proteins. In conclusion, we have demonstrated that DPH can be bioactivated in human liver to metabolites capable of covalently binding to proteins. The relationship of adduct formation to DPH-induced hypersensitivity reactions remains to be clarified.
Similar articles
-
Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation.Drug Metab Dispos. 2000 Aug;28(8):945-50. Drug Metab Dispos. 2000. PMID: 10901705
-
Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats.Drug Metab Dispos. 2001 Apr;29(4 Pt 1):427-34. Drug Metab Dispos. 2001. PMID: 11259327
-
NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine.Chem Res Toxicol. 2007 Nov;20(11):1649-57. doi: 10.1021/tx700132x. Epub 2007 Oct 2. Chem Res Toxicol. 2007. PMID: 17907785
-
Oxidative damage in chemical teratogenesis.Mutat Res. 1997 Dec 12;396(1-2):65-78. doi: 10.1016/s0027-5107(97)00175-9. Mutat Res. 1997. PMID: 9434860 Review.
-
Brief historical overview and recent progress on cytochromes P450: adaptation of aerobic organisms to their chemical environment and new mechanisms of prodrug bioactivation.Ann Pharm Fr. 2011 Jan;69(1):62-9. doi: 10.1016/j.pharma.2010.11.001. Epub 2010 Dec 30. Ann Pharm Fr. 2011. PMID: 21296219 Review.
Cited by
-
Green electrosynthesis of drug metabolites.Toxicol Res (Camb). 2023 Mar 7;12(2):150-177. doi: 10.1093/toxres/tfad009. eCollection 2023 Apr. Toxicol Res (Camb). 2023. PMID: 37125339 Free PMC article. Review.
-
A history of the roles of cytochrome P450 enzymes in the toxicity of drugs.Toxicol Res. 2020 Aug 18;37(1):1-23. doi: 10.1007/s43188-020-00056-z. eCollection 2021 Jan. Toxicol Res. 2020. PMID: 32837681 Free PMC article. Review.
-
Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment.Drug Saf. 2000 Dec;23(6):483-507. doi: 10.2165/00002018-200023060-00002. Drug Saf. 2000. PMID: 11144658 Review.
-
Herb-drug interactions: a literature review.Drugs. 2005;65(9):1239-82. doi: 10.2165/00003495-200565090-00005. Drugs. 2005. PMID: 15916450 Review.
-
Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine.Drug Metab Dispos. 2008 Aug;36(8):1637-49. doi: 10.1124/dmd.107.019562. Epub 2008 May 7. Drug Metab Dispos. 2008. PMID: 18463198 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous